1.Walker, JJ. Pre-eclampsia. Lancet 2000; 356: 1260–5.
2.Main, EK, McCain, CL, Morton, CH, et al. Pregnancy related mortality in California: causes, characteristics, and improvement opportunities. Obstet Gynecol 2015; 125: 938–47.
3.American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122(5): 1122–31.
4.National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–22.
5.Rogers, LK, Velten, M. Maternal inflammation, growth retardation, and preterm birth: insights into adult cardiovascular disease. Life Sci 2011; 89: 417–21.
6.Markham, KB, Funai, EF. Pregnancy-related hypertension. In Creasy, RK, Resnik, R, Iams, JD, et al., eds., Maternal-Fetal Medicine: Principles and Practice, 7th edn. Philadelphia: Saunders, 2014: 856–81.
7.American Congress of Obstetricians and Gynecologists (ACOG). Diagnosis and Management of Preeclampsia and Eclampsia (American Congress of Obstetricians and Gynecologists Practice Bulletin Number 33), ACOG, Washington, DC, 2002 (reaffirmed 2012).
8.Spong, CY, Mercer, BM, D’Alton, M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118: 323–33.
9.Abalos, A, Duley, L, Steyn, DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014; 2: CD002252
10.Magee, L.A., Elran, E., Bull, S.B., et al: Risks and benefits of beta receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 2000; 88: 15–26.
11.Magee, LA, von Dadelszen, P, Rey, E, et al. The control of hypertension in pregnancy study (CHIPS) randomized controlled trial. Pregnancy Hypertens 2015; 5: 2.
12.Buchbinder, A, Sibai, BM, Caritis, S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186: 66–71.
13.Saudan, P, Brown, MA, Buddle, ML, et al. Does gestational hypertension become pre-eclampsia. Br J Obstet Gynaecol 1998; 105: 1177–84.
14.Wu, Y, Xiong, X, Fraser, WD, et al. Association of uric acid with progression to preeclampsia and development of adverse conditions in gestational hypertensive pregnancies. Am J Hypertens 2012; 25: 711–17.
15.Sibai, BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163: 1049–54.
16.North, RA, Taylor, RS, Schellenberg, JC. Evaluation of a definition of preeclampsia. Br J Obstet Gynaecol 1999; 106: 767–73.
17.Woelkers, D, Barton, J, von Dadelszen, P, et al. Rates of adverse outcomes are elevated in preterm patients with suspected hypertensive disorders without diagnostic criteria for preeclampsia. Pregnancy Hypertens 2015; 5: 39.
18.Abalos, E, Cuesta, C, Grosso, AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170: 1–7.
19.Sibai, BM, Barton, JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 2007; 196: 514.e1–9.
20.Sibai, BM. Pre-eclampsia. Lancet 2005; 365: 785–99.
21.Wang, A, Rana, S, Karumanchi, SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 2009; 24: 147–58.
22.Ness, RB, Sibai, BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gyncol 2006; 195: 40–9.
23.Sibai, BM. Management of late preterm and early-term pregnancies complicated by mild gestational hypertension/pre-eclampsia. Semin Perinatol 2011; 35: 292–6.
24.Bombrys, AE, Barton, JR, Nowacki, EA, et al. Expectant management of severe pre-eclampsia at less than 27 weeks’ gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol 2008; 199: 247.e1–6.
25.Sibai, BM. Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. Am J Obstet Gynecol 2004; 190: 1520–6.
26.Altman, D, Carroli, G, Duley, L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulfate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 1: 1877–90.
27.Resnik, R, Creasy, RK. Intrauterine growth restriction. In Creasy, RK, Resnik, R, Iams, JD, et al., eds., Maternal-Fetal Medicine: Principles and Practice, 7th edn. Philadelphia: Saunders, 2014: 743–55.
28.Friedman, SA, Schiff, E, Kao, L, et al. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 1995; 172: 1785–92.
29.Mendola, P, Mumford, SL, Mannisto, TI, et al. Controlled direct effects of preeclampsia on neonatal health after accounting for mediation by preterm birth. Epidemiology 2015; 26: 17–26.
30.Riaz, M, Porat, R, Brodsky, NL, et al. The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol 1998; 18: 449–54.
31.Greenberg, MB, Penn, AA, Whitaker, KR, et al. Effect of magnesium sulfate exposure on term neonates. J Perinatol 2013; 33: 188–93.
32.Rouse, D, Hirtz, DG, Thom, E, et al. A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359: 895–905.
33.Constantine, MM, Weiner, SJ. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Obstet Gynecol 2009; 114: 354–64.
34.Duley, L, Meher, S, Jones, L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013; 7: CD001449.
35.Cooper, WO, Hernandez-Diaz, S, Arbogast, PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443–51
36.Magee, LA, Cham, C, Waterman, EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327: 955–64.
